Ussher, J. R. & Drucker, D. J. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat. Rev. Cardiol. 20, 463–474 (2023).

Article  PubMed  CAS  Google Scholar 

Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2413258 (2025).

Article  PubMed  Google Scholar 

Loomba, R. et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 8, 511–522 (2023).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Aronne, L. J. et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2416394 (2025).

Article  PubMed  Google Scholar 

Loomba, R. et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N. Engl. J. Med. 391, 299–310 (2024).

Article  PubMed  CAS  Google Scholar 

Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653–662 (2021).

Article  PubMed  CAS  Google Scholar 

Celsa, C. et al. Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies. Gut 74, 815–824 (2025).

Article  PubMed  CAS  Google Scholar 

Tilg, H., Adolph, T. E. & Moschen, A. R. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade. Hepatology 73, 833–842 (2021).

Article  PubMed  Google Scholar 

Ben Nasr, M. et al. Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule. Cell Metab. 36, 1302–1319.e12 (2024).

Article  PubMed  Google Scholar 

Moschen, A. R. et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor α expression. Gut 59, 1259–1264 (2010).

Article  PubMed  CAS  Google Scholar